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Abstract. The use of combinations of inexpensive drugs for the treatment of malaria in Africa has been proposed as
an interim policy while awaiting the widespread availability of more effective regimens. We compared sulfadoxine-
pyrimethamine plus chloroquine or amodiaquine in three districts in Uganda. Patients aged 6 months or greater with
uncomplicated falciparum malaria were enrolled and randomized to therapy. Safety, tolerability, and efficacy outcomes,
adjusted by genotyping, were assessed over 28 days. Of 1,105 patients enrolled, 1,057 (96%) completed follow-up. For
children less than 5 years old, the risk of clinical treatment failure adjusted by genotyping at the three sites ranged from
34% to 67% with chloroquine plus sulfadoxine-pyrimethamine and from 13% to 35% with amodiaquine plus sulfadox-
ine-pyrimethamine (risk differences 21–32%, P < 0.0001 at all sites). Serious adverse events were uncommon with both
regimens. The risk of treatment failure with chloroquine plus sulfadoxine-pyrimethamine, the current standard in
Uganda, was unacceptably high. Amodiaquine plus sulfadoxine-pyrimethamine was significantly more efficacious; how-
ever, existing levels of resistance raises concern about the useful therapeutic life-span of this regimen.
INTRODUCTION
Malaria remains one of the most serious global health prob-
lems. In sub-Saharan Africa, the spread of resistance to the
widely available and inexpensive drugs chloroquine (CQ) and
sulfadoxine-pyrimethamine (SP) poses a major threat to tar-
gets to halve the malaria burden by the year 2010.1 Indeed,
the continued use of ineffective drugs has been linked to in-
creased malarial incidence and mortality.2,3 Few effective, af-
fordable antimalarial agents are currently available, and ap-
propriate alternatives to CQ and SP have been difficult to
identify. One alternative regimen, amodiaquine (AQ) plus
SP, has shown surprisingly good efficacy in Uganda,4–6 al-
though concerns persist about its effectiveness in different
geographical settings and over time. Many authorities have
strongly advocated the use of combination antimalarial regi-
mens in Africa, particularly artemisinin-based combination
therapy (ACT),7 but implementation of this recommendation
is complicated by limited clinical experience with newer regi-
mens and the higher cost of artemisinins.
To reevaluate antimalarial treatment policies, in 1997
Uganda’s Malaria Control Program (MCP), with the support
of the East African Network for Monitoring Antimalarial
Treatment (EANMAT), established seven sentinel sites rep-
resentative of the various geographical, epidemiologic, and
ecological strata of malaria in Uganda. Studies at 6 of these
sites in 1998–1999 demonstrated median clinical failure rates
in children aged 6–59 months of 28% for CQ (range, 10–46%)
and 10% for SP (range, 0–18%).8 However, these studies
were limited by small sample sizes, noncomparative study
designs, and a 14-day follow-up period, which may have sig-
nificantly underestimated the true risk of treatment failure.4
In June 2000, the combination of CQ + SP was selected to
replace CQ as first-line treatment of uncomplicated malaria,
although limited efficacy data for this combination were avail-
able. In Kampala, CQ + SP was subsequently shown to be
more efficacious than SP monotherapy but inferior to AQ +
SP after 14 days of follow-up.5 The choice of CQ + SP was not
ideal, as it consists of two drugs that are clearly failing,7 but its
implementation was necessitated by the urgent need to re-
place CQ monotherapy and a shortage of efficacy data for
other therapies, especially from Uganda. In this regard, im-
mediate interest focused on the possibility of replacing CQ +
SP with AQ + SP, which is currently available and has shown
surprisingly strong efficacy in three studies in Kampala4–6 but
had not been studied in other regions of Uganda.
Here, we describe the establishment of an expanded na-
tional program to monitor antimalarial drug resistance in
Uganda based on the EANMAT model and report the results
of a multisite randomized clinical trial comparing the efficacy,
safety, and tolerability of CQ + SP versus AQ + SP. We show
that multisite randomized clinical trials, with long-term fol-
low-up, molecular genotyping, and full safety assessment, can
be conducted within a Ministry of Health framework to gen-
erate the best available evidence to guide policy decisions.
We also discuss the implications of our results for antimalarial
drug policy in Uganda.
MATERIALS AND METHODS
Organizational structure and study sites. The Uganda Ma-
laria Surveillance Project (UMSP) was formed as a collabo-
rative effort between the Ugandan Ministry of Health
(MOH) and academic researchers to build local capacity and
implement a multisite surveillance system to evaluate the
comparative efficacy, safety, and tolerability of antimalarial
therapies for the development of evidence-based treatment
policy. The UMSP organization consists of a core facility,
which provides training, logistical support, data management
and quality control, and study teams working at seven
sentinel sites around Uganda. Sentinel sites, which are based
within public health facilities, were previously selected to be
representative of the range of ecological and epidemiologic
conditions by the Ugandan MCP in collaboration with
EANMAT.9 In this report we present results from our first
three studies, which were conducted between December 2002
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and June 2003 at sites in Kanungu, Kyenjojo, and Mubende
districts. All sites are rural, with two annual peaks in rainfall
and medium to high malaria transmission intensity (Ugandan
MOH, unpublished data). A common protocol was approved
by the Ugandan National Council for Science and Technol-
ogy, and institutional review boards at the University of Cali-
fornia, San Francisco, and the University of California,
Berkeley.
Recruitment. All patients who presented to the sentinel site
health centers with symptoms suggestive of malaria and a
positive screening thick blood smear were referred to study
physicians for further evaluation. Consecutive patients were
screened for the following selection criteria: 1) age 6 months
or greater; 2) history of fever in the last 24 hours or axillary
temperature greater or equal to 37.5°C; 3) no history of seri-
ous side effects to study medications; 4) no evidence of a
concomitant febrile illness; 5) provision of informed consent;
6) ability to participate in 28-day follow-up; 7) no history of
treatment with an antifolate or AQ during the previous week;
8) absence of pregnancy based on history of last menstrual
period; and 9) no danger signs (prostration, inability to drink,
recent convulsion, persistent vomiting) or evidence of severe
malaria.10 The final selection criteria, including: 10) Plasmo-
dium falciparum monoinfection; 11) parasite density 2000/L
to 200,000/L; and 12) hemoglobin  5.0 g/dL, were assessed
after enrollment. Because laboratory results were not avail-
able until the following day, a patient could be excluded after
randomization. Patients with persistent vomiting of study
medications on Day 0 were also excluded.
Baseline evaluation, randomization, and treatment alloca-
tion. At enrollment, patients or their parents/guardians were
questioned regarding prior antimalarial therapy, use of other
medications, and common symptoms. Temperature (axillary)
and weight were measured, and a physical examination was
performed. Blood was obtained by fingerprick for thick and
thin blood smears, hemoglobin measurement, and storage on
filter paper for molecular analysis. Patients were randomly
assigned to receive one of two oral treatments: CQ plus SP or
AQ plus SP. Medications were dosed as follows: chloroquine
(Cosmoquin, Cosmos, 150 mg base tablets, 25 mg/kg, maxi-
mum dose 1500 mg base) 10 mg/kg on Days 0 and 1, and 5
mg/kg on Day 2; SP (Fansidar, Roche, 500 mg/25 mg tablets,
25 mg/kg of sulfadoxine and 1.25 mg/kg of pyrimethamine,
maximum dose 3 tablets) as a single dose; and amodiaquine
(Camoquin, Parke-Davis, 200 mg base tablets, 25 mg/kg,
maximum dose 1500 mg base) 10 mg/kg on Days 0 and 1, and
5 mg/kg on Day 2.
Randomization codes were computer-generated for two
age groups (6–59 months and 5 years or older) by an off-site
investigator. Randomization codes were provided to a study
nurse who was responsible for treatment allocation. Patients
were not informed of their treatment regimen, and all other
study personnel were blinded to the treatment assignments.
Study medications were administered by the study nurse ac-
cording to weight-based guidelines for administration of frac-
tions of tablets modified from World Health Organization
(WHO) recommendations.11 Patients were directly observed
for 30 minutes after treatment and the dose was readminis-
tered if vomiting occurred. Patients who vomited persistently
were excluded from the study and referred for treatment with
parenteral quinine. All patients were provided with a 3-day
supply of acetaminophen for treatment of febrile symptoms.
Children with hemoglobin levels less than 10.0 g/dL were
treated according to Integrated Management of Childhood
Illness guidelines with ferrous sulfate for 14 days and given
antihelminthic treatment if they were more than 1 year of age
and had not been treated in the previous 6 months.
Follow-up procedures. Patients were asked to return for
follow-up visits on days 1, 2, 3, 7, 14, 21, 28, and any other day
when they felt ill. On each visit, a complete history was taken
and physical examination performed. Blood was obtained by
fingerprick on all follow-up days, except Day 1, for thick
blood smears and storage on filter paper. Hemoglobin mea-
surement was repeated on Day 28 or the day of clinical treat-
ment failure. If patients did not return for follow-up, they
were visited at home.
Laboratory procedures. Initial screening blood smears
were stained with 10% Giemsa for 10 minutes. Thick and thin
blood smears used in the study were stained with 2% Giemsa
for 30 minutes. Parasite densities were determined from thick
blood smears by counting the number of asexual parasites per
200 WBCs (or per 500, if the count was less than 10 parasites/
200 WBCs) and calculating parasites/microliter assuming a
WBC count of 8,000/L. A smear was considered negative if
no parasites were seen after review of 100 high-powered
fields. Gametocytemia was also assessed from thick blood
smears. Thin blood smears were reviewed to detect non-
falciparum infections. Hemoglobin measurements were made
using a portable spectrophotometer (HemoCue, Anglholm,
Sweden). Filter paper blood samples collected at enrollment
and on the day of clinical or parasitological failure were as-
sessed with molecular genotyping performed at University of
California, San Francisco, to distinguish recrudescent and
new infections. For patients with recurrent parasitemia after
Day 4, samples from enrollment and the time of failure were
analyzed for polymorphisms in merozoite surface protein-2
(MSP-2), according to previously published methods.12 Out-
comes were classified as recrudescences (true treatment fail-
ure) if all MSP-2 alleles present on the day of recurrence were
present at enrollment and as a new infection if this was not
the case. Samples with unsuccessful genotyping (1%) were
classified as recrudescences. The potential limitation of this
classification is the possibility that posttreatment samples
truly do contain both recrudescent parasites and newly infect-
ing strains (mixed results) thus underestimating true failure.
Quality control. Study sites were visited every 2 weeks to
monitor study procedures. After each site visit, blood slides
were brought to the core facility to assess slide quality and
accuracy of microscopy readings. At the beginning of each
study, all slides were re-read by senior laboratory technicians.
Once error rates were less than 10%, a random sample of
10% of slides was reviewed. A third reviewer reconciled dis-
cordant results.
Adverse event reporting. At each follow-up visit, patients
were assessed for any new or worsening event. An adverse
event was defined as any untoward medical occurrence, irre-
spective of its suspected relationship to the study medications
as per International Conference of Harmonization (ICH)
guidelines (Guidance for Industry Good Clinical Practice:
Consolidated Guidance [ICH E6], April 1996). All events
were graded by severity (none, mild, moderate, severe, life-
threatening). Relationship to the study medications (none,
unlikely, possible, probable, or definite) was recorded for
events of moderate or greater severity according to a system
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developed using guidelines from the World Health Organiza-
tion (Toxicity Grading Scale for Determining the Severity of
Adverse Events) and the National Institutes of Health, Divi-
sion of Microbiology and Infectious Diseases (Pediatric Tox-
icity Tables, May 2001). A serious adverse event was defined
as any adverse experience that resulted in death; life-
threatening experience; hospitalization; persistent or signifi-
cant disability or incapacity; or specific medical or surgical
intervention to prevent serious outcome.
Assessment of treatment response. Day 28 treatment out-
comes were classified according to WHO guidelines for areas
of intense transmission as adequate clinical and parasitologi-
cal response (ACPR), early treatment failure (ETF), late
clinical failure (LCF), and late parasitological failure (LPF).10
The criteria for LCF was modified to include history of fever
within the previous 24 hours on Days 4–28 with parasitemia.
The classification of LPF, defined as parasitemia in the ab-
sence of fever on day 28, was made at the end of study follow-
up. Patients classified as treatment failures (ETF, LCF, LPF)
were given rescue therapy with quinine. Clinical outcomes
were stratified into success (ACPR/LPF) or failure (ETF/
LCF). Parasitological outcomes were stratified into success
(ACPR) or failure (ETF/LCF/LPF). All treatment failures
were treated with quinine (10 mg//kg three times daily for 7
days). Patients were not assigned an outcome if any of the
following occurred: 1) use of antimalarial drugs outside of the
study protocol; 2) parasitemia in the presence of a febrile,
nonmalarial illness diagnosed by the study physician; 3) with-
drawal of consent; and 4) loss to follow-up.
Statistical analysis. Sample size was calculated for each site
to test the hypothesis that treatment with AQ + SP would
decrease the risk of Day 28 clinical failure adjusted for geno-
typing compared with CQ + SP (two-sided  of 0.05 and
power of 80%). The risk of treatment failure was estimated to
be 15% for CQ + SP and 5% for AQ + SP. Allowing for 10%
exclusion after enrollment, the samples sizes per group were
176 for each site.
Data were double-entered (EpiInfo 6.04, Centers for Dis-
ease Control and Prevention, Atlanta, GA), verified, and ana-
lyzed using SPSS version 10.0 (SPSS, Inc., Chicago, IL) and
Stata version 7.0 (Stata Corporation, College Station, TX).
Efficacy data were evaluated using a per-protocol analysis,
which only included patients with treatment outcomes. An
age-stratified analysis for patients less than 5 years of age and
patients 5 years or older was planned. Parasite densities were
normalized using logarithmic transformation. Categorical
variables were compared using 2 or Fisher’s exact test, and
continuous variables were compared using an independent
samples t test. The primary efficacy outcomes were 28-day
clinical and parasitological failure risks both unadjusted and
adjusted by genotyping. Risks of clinical and parasitological
treatment failure unadjusted by genotyping were expressed as
simple proportions. Risks of clinical and parasitological treat-
ment failure after adjustment by genotyping were estimated
using Kaplan-Meier survival analysis techniques in accor-
dance with the new WHO protocol.10 With survival analysis,
data were censored for new infections. Hypothesis testing was
made using risk differences, exact 95% confidence intervals,
and P values. Secondary outcomes included clinical outcomes
at Day 14, fever clearance, parasite clearance, change in he-
moglobin levels between Day 0 and the last day of follow-up,
presence of gametocytes during follow-up, and the incidence
of adverse events. A P value (two-tailed) of less than 0.05 was
considered statistically significant.
Role of the funding source. The funding source played no
role in protocol development, data collection, data analysis,
data interpretation, or in the writing of the report.
RESULTS
Patient characteristics. Of 1,973 patients referred for evalu-
ation at our 3 sites during the study period, 763 were excluded
during screening and 105 were excluded after treatment as-
signment but before enrollment (Figure 1). Reasons for ex-
clusion after treatment assignment included non-falciparum
malaria infection (N 34), parasite density < 2,000/L (N
26) or > 200,000/L (N  34), hemoglobin < 5.0 g/dL (N 
2), persistent vomiting of study medications on Day 0 (N 
7), and inappropriate consent (N  2). Of the 1,105 patients
enrolled, 1057 (96%) were assigned efficacy outcomes. Rea-
sons for exclusion after enrollment included loss to follow-up
(N 25), withdrawal of consent (N 12), use of antimalarial
medications outside of the study protocol (N  10), and de-
velopment of a concomitant febrile illness that interfered with
classification of treatment outcome (N  1). In addition, all
patients screened (N  221) and enrolled (N  124) during
a 1-month period from one site (Mubende) were excluded
due to a systematic error in the classification and manage-
ment of LPFs. Due to a misunderstanding about the new
WHO classification system, patients with asymptomatic par-
asitemia after Day 3 but before Day 28 were classified as
LPFs and treated with quinine. For this reason, we were un-
able to assess whether these patients would have gone on to
become late clinical failures, late parasitological failures, or
adequate parasitological and clinical responses at the comple-
tion of the full 28-day follow-up period. To best prevent the
introduction of bias in our results, we decided to exclude the
entire cohort of patients enrolled at this site during the
1-month period when the error occurred. Among patients
with treatment outcomes, there were no statistically signifi-
cant differences in baseline characteristics between the two
treatment groups at each site. However, there were statisti-
cally significant differences between the sites for age distri-
bution, prior use of antimalarials, mean temperature, mean
hemoglobin, and the presence of gametocytes (Table 1).
Treatment efficacy. The 1,057 patients with efficacy out-
comes were stratified by age (age less than 5 years versus 5
years or older). Considering all sites, in children less than 5
years old, the risk of early treatment failure was higher with
CQ + SP compared with AQ + SP, but this did not reach
statistical significance (7% versus 4%, P  0.09). In patients
5 years or older, early treatment failure occurred in only 1 of
159 patients receiving CQ + SP and 1 of 161 patients receiving
AQ + SP. At Day 14, CQ + SP was significantly inferior to
AQ + SP in children under 5 years of age, considering both
clinical failure unadjusted by genotyping (34% versus 10%,
risk difference 24%, 95% CI: 18–29%, P < 0.0001) and clinical
failure after adjustment by genotyping (22% versus 8%, risk
difference 14%, 95% CI: 4–24%, P  0.005). However, lim-
iting follow-up to 14 days seriously underestimated the risk of
clinical treatment failure in both treatment groups. A similar
trend was observed for older patients (data not shown).
Considering 28-day outcomes at all sites in patients less
than 5 years of age, the risk of clinical failure unadjusted by
MULTISITE TRIAL OF COMBINATION ANTIMALARIAL THERAPY 575
genotyping ranged from 70% to 86% with CQ + SP and 35%
to 53% with AQ + SP (risk differences 26–35%, P < 0.0001 at
all sites) (Table 2). After adjustment by genotyping, the risk
of clinical treatment failure ranged from 34% to 67% with
CQ + SP and 13% to 35% with AQ + SP (risk differences
21–32%, P  0.001 at all sites) (Table 2). Notably, despite
differences in risks of clinical failure unadjusted and adjusted
by genotyping, the benefit of AQ + SP over CQ + SP was
fairly consistent from site to site. Considering parasitological
outcomes, risks of failure unadjusted by genotyping ranged
from 81% to 91% with CQ + SP and 50% to 59% with AQ +
SP (risk difference 30–35%, P  0.001 at all sites). The risk of
FIGURE 1. Trial profile.
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parasitological failure adjusted by genotyping ranged from
43% to 73% with CQ + SP and 14% to 38% with AQ + SP
(risk difference 29–35%, P  0.001 at all sites) (Table 2).
The risk of treatment failure was considerably lower for
patients 5 years of age or greater compared with young chil-
dren. Considering 28-day outcomes, the risk of clinical failure
unadjusted by genotyping ranged from 31% to 42% with CQ
+ SP and 13% to 31% with AQ + SP (risk differences 1–29%,
P  0.05 at 2 sites). After adjustment by genotyping, the risk
of clinical treatment failure ranged from 13% to 21% with
CQ + SP and 3% to 12% with AQ + SP (risk differences
9–10%, P < 0.05 at 1 site). Considering parasitological out-
comes, risks of failure unadjusted by genotyping ranged from
52% to 60% with CQ + SP and 28% to 44% with AQ + SP
(risk difference 16–28%, P < 0.001 at 1 site). The risk of
parasitological failure adjusted by genotyping ranged from
21% to 40% with CQ + SP and 10% to 18% with AQ + SP
(risk difference 10–22%, P  0.05 at 1 site) (Table 2).
Secondary outcomes. Patients treated with AQ + SP had a
significantly lower risk of parasitemia on Day 3 at all three
sites (Table 3). The proportion of patients with fever on Days
1–3 was lower in the AQ + SP group; however, the results
were statistically significant only on Day 2 in Kanungu. Ga-
metocyte carriage during follow-up was lower in the AQ + SP
group, but this difference was statistically significant only in
Mubende and was of borderline significance in Kanungu. Pa-
tients treated with AQ + SP had a significantly greater in-
crease in mean hemoglobin at all three sites.
Adverse events. Adverse events, broadly defined as any
untoward medical occurrences, occurred commonly. A total
of 4,767 events were reported, with 1,007 of 1,057 (95%) pa-
tients completing follow-up experiencing at least 1 event;
these events were primarily mild or moderate in severity. A
comparison of the most commonly reported adverse events
for all study sites combined is presented in Table 4. Consid-
ering the occurrence of any adverse event, cough and coryza
were significantly more common in the AQ + SP group,
whereas elevated temperature, subjective fever, and decrease
TABLE 1
Baseline characteristics of patients with efficacy outcomes
Kyenjojo Mubende Kanungu
CQ + SP AQ + SP CQ + SP AQ + SP CQ + SP AQ + SP
Number 170 179 180 171 173 184
Median age in years (IQR) 3.8 (1.6–9.0) 5.0 (2.3–11.0) 1.8 (1.2–6.0) 1.7 (1.0–3.6) 2.0 (1.3–3.9) 1.8 (1.2–4.3)
Age less than 5 years, no. (%) 96 (57%) 89 (50%) 130 (72%) 139 (81%) 138 (80%) 145 (79%)
Any antimalarial use previous 2 weeks, no. (%) 29 (17%) 35 (20%) 0 2 (1%) 71 (41%) 75 (41%)
Mean temperature (°C) (SD) 37.5 (1.4) 37.5 (1.3) 38.2 (1.0) 38.2 (0.9) 37.9 (1.3) 37.6 (1.3)
Geometric mean asexual parasites/L 27574 24620 22275 18702 23185 25068
Mean hemoglobin (g/dL) (SD) 10.4 (2.3) 11.0 (2.6) 9.8 (2.1) 9.4 (2.0) 9.2 (2.2) 9.2 (2.1)
Gametocytes present, no. (%) 41 (24%) 41 (23%) 28 (16%) 26 (15%) 7 (4%) 3 (2%)
IQR, intraquartile range.
TABLE 2
Treatment outcomes stratified by age for each study site
Age less than 5 years Age 5 years or greater
CQ + SP AQ + SP RD (95% CI) P value CQ + SP AQ + SP RD (95% CI) P value
Kyenjojo N 96 N 89 N 74 N 90
Risk of clinical failure
Unadjusted by genotyping* 70% 35% 35% (21–48%) < 0.0001 42% 13% 29% (15–42%) 0.0001
Adjusted by genotyping† 37% 14% 23% (9–37%) 0.001 13% 3% 10% (1–19%) 0.03
Risk of parasitological failure
Unadjusted by genotyping‡ 86% 52% 35% (22–47%) < 0.0001 55% 28% 28% (13–42%) 0.0004
Adjusted by genotyping§ 58% 24% 35% (19–51%) < 0.0001 21% 10% 10% (−2–22%) 0.10
Mubende N 130 N 139 N 50 N 32
Risk of clinical failure
Unadjusted by genotyping* 70% 44% 26% (15–38%) < 0.0001 38% 16% 22% (4–41%) 0.05
Adjusted by genotyping† 34% 13% 21% (10–32%) 0.0001 13% 3% 10% (−2–22%) 0.11
Risk of parasitological failure
Unadjusted by genotyping‡ 81% 50% 30% (20–41%) < 0.0001 52% 31% 21% (0–42%) 0.07
Adjusted by genotyping§ 43% 14% 29% (18–41%) < 0.0001 26% 10% 16% (−2–33%) 0.08
Kanungu N 138 N 145 N 35 N 39
Risk of clinical failure
Unadjusted by genotyping* 86% 53% 32% (22–42%) < 0.0001 31% 31% 1% (−20–22%) 1.0
Adjusted by genotyping† 67% 35% 32% (20–45%) < 0.0001 21% 12% 9% (−7–25%) 0.28
Risk of parasitological failure
Unadjusted by genotyping‡ 91% 59% 33% (23–42%) < 0.0001 60% 44% 16% (−6–39%) 0.17
Adjusted by genotyping§ 73% 38% 35% (23–47%) < 0.0001 40% 18% 22% (0–43%) 0.05
RD, risk difference.
* Proportion of patients with ETF or LCF
† Risk of ETF or LCF due to recrudescence using Kaplan-Meier product limit formula (LCF due to new infections censored)
‡ Proportion of patients with ETF or LCF or LPF
§ Risk of ETF or LCF/LPF due to recrudescence using Kaplan-Meier product limit formula (LCF/LPF due to new infections censored)
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in hemoglobin were significantly more reported in the CQ +
SP group. To focus on adverse events most likely related to
study medications, patients with treatment failure were re-
moved and analyses restricted to events of moderate or
greater severity at least probably related to study medica-
tions. In these restricted analyses, the proportions of patients
with relevant adverse events were not significantly different
between the two treatment groups (Table 4).
A total of 41 serious adverse events were reported in 37
patients, and there were no statistically significant differences
in the reporting of serious adverse events between the two
treatment groups. Serious adverse events included convul-
sions (N  15), vomiting (N  13), severe anemia (N  6),
weakness (N  3), elevated temperature (N  2), abnormal
chest exam (N  1), and leg swelling (N  1). No deaths
occurred. Thirty-four of 41 (83%) serious adverse events oc-
curred in patients with clinical treatment failure. Considering
the suspected relationship to treatment, 18 were unlikely, 19
were possibly, and 4 (all vomiting) were probably related to
study medications.
DISCUSSION
We conducted a multisite clinical trial in rural Uganda com-
paring CQ + SP, the standard-of-care for treatment of un-
complicated malaria, to AQ + SP, an inexpensive alternative.
Our studies demonstrate that African malaria control pro-
grams can perform “state-of-the-art” antimalarial drug effi-
cacy studies at rural sites. Specifically, our studies included
randomized, single-blinded comparisons of combination
therapies, 28-day follow-up with genotyping to discriminate
recrudescence from new infections, comprehensive quality
control, and assessment of safety and tolerability. Despite the
inherent complexity of conducting a multisite study in rural
Africa, we achieved excellent completion rates (> 95%) and
collected high-quality data to guide national antimalarial
treatment policy.
The World Health Organization (WHO) has provided stan-
dardized guidelines for the assessment of antimalarial drug
efficacy, designed to collect minimal essential information
about treatment response among populations at greatest
risk.10 These guidelines were recently updated to address pre-
vious methodological problems, producing a single standard-
ized protocol adaptable to different transmission levels. Our
methods differed slightly from those advocated by the
WHO10 in that we directly compared treatment regimens us-
ing a single-blinded randomized trial design.
In this study, the risk of clinical and parasitological failure
to CQ + SP was found to be unacceptably high in three rural
TABLE 4
Comparison of adverse events across all study sites
Any adverse event
Adverse events of moderate or greater
severity and probable/definite relationship*
CQ + SP AQ + SP P value CQ + SP AQ + SP P value
Symptoms
Fever 360/522 (69%) 298/534 (56%) < 0.0001 31/186 (17%) 52/336 (15%) 0.71
Cough 249/522 (48%) 306/534 (57%) 0.002 2/186 (1%) 6/336 (2%) 0.72
Weakness 233/522 (45%) 226/534 (42%) 0.46 7/186 (4%) 20/336 (6%) 0.31
Headache 88/217 (41%) 91/232 (39%) 0.85 3/114 (3%) 1/183 (1%) 0.16
Anorexia 201/522 (39%) 213/534 (40%) 0.66 11/186 (6%) 25/336 (7%) 0.59
Abdominal pain 77/218 (35%) 91/233 (39%) 0.44 2/114 (2%) 0/184 (0%) 0.15
Coryza 149/522 (29%) 183/534 (34%) 0.05 1/186 (1%) 2/336 (1%) 1.0
Vomiting 151/522 (29%) 144/534 (27%) 0.49 9/177 (5%) 7/336 (2%) 0.11
Diarrhea 135/522 (26%) 140/534 (26%) 0.94 1/186 (1%) 3/336 (1%) 1.0
Pruritis 114/522 (22%) 98/533 (18%) 0.17 22/186 (12%) 27/335 (8%) 0.16
Physical exam findings
Temperature 218/522 (42%) 159/534 (30%) 0.0001 4/186 (2%) 12/336 (4%) 0.43
Abdomen 77/522 (15%) 83/534 (16%) 0.67 0/186 (0%) 0/336 (0%) 1.0
Chest 58/522 (11%) 67/534 (13%) 0.51 0/186 (0%) 2/336 (1%) 0.54
Skin 42/522 (8%) 45/534 (8%) 0.82 4/186 (2%) 8/336 (2%) 1.0
Laboratory
Decline in hemoglobin† 114/484 (24%) 63/519 (12%) < 0.0001 5/183 (3%) 10/334 (3%) 1.0
* Excluding clinical treatment failures.
† Any  decline in Hb to < 10 mg/dL; moderate or greater severity  decline in Hb to < 9 mg/dL.
TABLE 3
Secondary treatment outcomes
Outcome
Kyenjojo Mubende Kanungu
CQ + SP AQ + SP P value CQ + SP AQ + SP P value CQ + SP AQ + SP P value
Proportion with parasitemia on Day 3 43% 21% < 0.0001 43% 9% < 0.0001 35% 19% 0.0008
Proportion with fever*
Day 1 85% 77% 0.06 97% 99% 0.45 82% 77% 0.36
Day 2 54% 49% 0.34 73% 72% 0.90 66% 50% 0.002
Day 3 18% 20% 0.59 38% 32% 0.26 32% 23% 0.08
Proportion with gametocytes
during follow-up† 42% 36% 0.31 45% 30% 0.009 30% 20% 0.06
Change in hemoglobin g/dL (SD)‡ 0.78 (1.9) 1.14 (1.4) 0.01 0.45 (1.8) 1.43 (1.8) < 0.0001 0.76 (1.9) 1.52 (2.0) < 0.0001
* Temperature  37.5°C or history of fever previous 24 hours.
† Only includes those patients with no gametocytes detected on Day 0.
‡ Hemoglobin on Day 28 or day of failure—Day 0 hemoglobin.
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sites around Uganda. Limiting follow-up to 14 days would
have seriously underestimated the risk of treatment failure, as
most failures occurred between 15 and 28 days after treat-
ment. This result is not surprising, as the long elimination
half-life of SP and complex nature of antimalarial drug resis-
tance may delay its clinical presentation.13 AQ + SP was su-
perior to CQ + SP considering both the need for rescue
therapy and the risk of true treatment failure (excluding new
infections). AQ + SP decreased the need for rescue therapy
for symptomatic illness by 31% in young children and by 20%
in older patients. This difference suggests that replacing CQ +
SP with AQ + SP could decrease the need for repeat therapy
of malaria and diminish the risk of progression to severe ill-
ness. However, AQ + SP is not an ideal long-term solution, as
resistance to both drugs is prevalent and likely increasing.
Indeed, the risk of clinical failure with AQ + SP in young
children was 35% at Kanungu, although this was still much
lower than that with CQ + SP (67%).
Our study also offered a rigorous comparison of the safety
and tolerability of the two tested regimens. Although, when
defined as any untoward medical occurrences, adverse events
were very common, drug-related adverse events appeared to
be uncommon and generally mild. No significant differences
in drug-related adverse events were seen between the two
tested regimens. It should be noted that this study was not
powered to detect rare, but serious toxicities, which have
been described with both SP and AQ, primarily in individuals
using the drugs for long-term chemoprophylaxis.14
Considering available data, how should the Uganda Ma-
laria Control Program proceed? Clearly, the recent decision
to abandon CQ + SP as first-line treatment is supported by
these results. However, the optimal replacement for CQ + SP
remains unclear. Artemisinin-based combination therapies
(ACT) have been strongly advocated for use in Africa,7 but
comparative data on the efficacy and safety of available regi-
mens are currently limited in this region. In addition, the high
cost and limited availability of these regimens remain barriers
to the implementation and sustainability of programs includ-
ing ACT.15 This concern is especially relevant given the em-
phasis on presumptive treatment of fevers with antimalarials
outside of the formal health sector as a cornerstone of malaria
control for Africa. In previous studies from Uganda and
Rwanda, SP + AS was shown to have a higher risk of treat-
ment failure compared with AQ + SP, both unadjusted and
adjusted for genotyping.4,16 Studies comparing CQ + SP, AQ
+ SP, and AQ + AS are currently ongoing in Uganda as part
of our national surveillance program. Given the available
data and the urgent need to replace CQ + SP, artemether-
lumefantrine was recently chosen as the provisional first-line
treatment of uncomplicated malaria in Uganda; however, in-
corporation of this regimen into the national drug policy, par-
ticularly in the home-based management of fever program,
will be challenging. AQ + SP could play a role in future
policy, either as an interim first-line regimen, pending wide-
spread availability of artemether-lumefantrine, or for use in
home-based management of fever. Our results suggest that
changing from CQ + SP to AQ + SP now could substantially
improve therapeutic efficacy. However, the useful therapeutic
life of AQ + SP may be limited by resistance to the individual
drugs. In Rwanda where AQ + SP is the first-line treatment
of uncomplicated malaria,16 resistance to this combination at
one site, which borders Uganda, was 29% in 2001
(EANMAT, unpublished data).
The drug efficacy “disaster” in sub-Saharan Africa neces-
sitates ongoing surveillance of antimalarial regimens cur-
rently in use and timely evaluation of newer therapies. The
WHO has provided basic guidelines to help guide this pro-
cess, and groups such as EANMAT and WHO/AFRO have
helped to coordinate national efforts. Our results demon-
strate that clinical trial networks can be established in Africa,
allowing for the collection of high-quality data on antimalarial
treatment efficacy. Implementation of multisite studies could
be done through existing partnerships. Comparative drug ef-
ficacy studies using the methodology described here could
improve the detection of drug resistance patterns and may
uncover dramatic differences in efficacy between available
regimens. Ideally, antimalarial drug policy decision-making
should be evidence-based, and efforts should be made to
maximize the quality of the data collected.
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